FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...
A clinical pathway blends expertise from many providers. The primary goal of a clinical pathway is to produce maximum value at each practice site. Dr Konduri’s institution strongly emphasizes the ...
Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data The robust and sustained clinical responses to ...
AUSTIN, Texas , Oct. 24, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
A male in his 50s presented with profound leucocytosis, systemic symptoms and marked hepatosplenomegaly. Initial workup with peripheral blood flow cytometry suggested T-cell prolymphocytic leukaemia ...
Many forms of cancer are devastating. But pancreatic cancer is one of the most deadly and aggressive forms there is. There are several reasons for this, including its stealthy progression, rapid ...
License includes Genprex's (GNPX) Reqorsa ® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung Cancer AUSTIN, Texas, Nov. 20, 2024 /PRNewswire/ -- Genprex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results